ELTX logo

ELTX
Elicio Therapeutics Inc

519
Mkt Cap
$189.91M
Volume
111,351.00
52W High
$14.93
52W Low
$5.80
PE Ratio
-4.24
ELTX Fundamentals
Price
$9.95
Prev Close
$9.90
Open
$9.99
50D MA
$10.95
Beta
0.75
Avg. Volume
124,115.86
EPS (Annual)
-$2.58
P/B
-129.07
Rev/Employee
$0.00
$117.84
Loading...
Loading...
News
all
press releases
Elicio Therapeutics (ELTX) to Release Earnings on Tuesday
Elicio Therapeutics (NASDAQ:ELTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-elicio-therapeutics-inc-stock...
News Placeholder
More News
News Placeholder
Elicio Therapeutics (NASDAQ:ELTX) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH
LADENBURG THALM/SH SH assumed coverage on Elicio Therapeutics in a research report on Wednesday. They set a "buy" rating and a $20.00 price target for the company...
News Placeholder
Elicio Therapeutics (NASDAQ:ELTX) Trading 1.6% Higher - Here's What Happened
Elicio Therapeutics (NASDAQ:ELTX) Trading 1.6% Higher - Should You Buy...
News Placeholder
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
Here is how Aura Biosciences, Inc. (AURA) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
News Placeholder
Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in Elicio Therapeutics (ELTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
News Placeholder
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?
Here is how Quest Diagnostics (DGX) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
News Placeholder
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why
Elicio Therapeutics (ELTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
<
...
1
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available